Oncology Clinical Trials
Structured PRO capture with EORTC QLQ-C30 and PRO-CTCAE, continuous AE monitoring, and remote symptom tracking for decentralized oncology trials.
Modernizing Oncology Trial Execution
Oncology trials are among the most complex in clinical research. Multi-arm designs, combination therapies, biomarker driven stratification, and intensive safety monitoring demand technology that can keep pace. Vitruvian Shield provides oncology-specific workflows purpose built for the unique challenges of cancer research.
From structured patient-reported outcome capture to continuous adverse event monitoring through wearable biosensors, every module is configured for the velocity and complexity of modern oncology programs in decentralized and hybrid settings.
Oncology-Specific Capabilities
Patient-Reported Outcomes
Structured PRO capture with validated instruments including EORTC QLQ-C30 and PRO-CTCAE, delivered via mobile app with longitudinal quality-of-life tracking for clinical, regulatory, and health economics endpoints.
Treatment Response Monitoring
Continuous wearable monitoring captures treatment response signals between visits, fatigue patterns, activity decline, vital sign changes, providing early indicators of efficacy or progression.
Symptom Burden Tracking
Validated oncology PRO instruments (EORTC QLQ-C30, FACT-G, PRO-CTCAE) delivered via mobile app. Track chemotherapy side effects, quality of life, and functional status in real-time.
Safety Signal Detection
AI powered monitoring identifies potential adverse events from lab trends, vital signs, and patient reported symptoms. Early detection of hepatotoxicity, cardiotoxicity, and immune-related events.
Biomarker-Driven Stratification
Integrate biomarker data into randomization and stratification workflows. Support for companion diagnostics, ctDNA tracking, and adaptive enrichment designs.
Multi-Arm Trial Support
Platform-level support for basket trials, umbrella trials, and adaptive designs with dynamic arm allocation, shared control groups, and master protocol management.
Study Details
Factual parameters of the oncology electronic survey pilot currently under activation.
VS-ONCO-eSURVEY-2026
Oncology Electronic Survey Pilot
Electronic survey pilot capturing quality-of-life and symptom burden in oncology patients via validated patient-reported outcome instruments, delivered through the Vitruvian Shield ePRO module.
- Study Identifier
- VS-ONCO-eSURVEY-2026
- Planned Enrollment
- 40–60 patients
- Per-Patient Duration
- Six months per patient
- Instruments & Devices
- EORTC QLQ-C30 and PRO-CTCAE validated instruments
- Clinical Setting
- Conducted in partnership with a leading Portuguese academic medical center, via the TEF-Health framework.
- Timeline
- Protocol v1.0 submitted 25 February 2026. Study activation targeted for May 2026.
Clinical site names are disclosed only with written publication consent. Study parameters current as of the latest protocol version.
A patient story
HIC01 — Loss of Donors
Ready to Modernize Your Clinical Trials?
Join leading sponsors, CROs, and research sites using Vitruvian Shield to run faster, smarter, and more compliant trials.
Or contact our team for a personalized walkthrough.